[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-340568-105":59,"doc-detail-340568-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","pgc-1-drives-small-cell-neuroendocrine-cancer-progression-toward-an-ascl1-expressing-subtype-with-increased-mitochondrial-capacity","PGC-1α drives small cell neuroendocrine cancer progression toward an ASCL1-expressing subtype with increased mitochondrial capacity","","Adenocarcinomas from multiple tissues can converge on treatment-resistant small cell neuroendocrine (SCN) cancers defined by ASCL1, POU2F3, NEUROD1, and YAP1 subtypes. The study tests how mitochondrial metabolism shapes SCN cancer progression by combining extensive bioinformatics across thousands of tumors and cancer cell lines with mechanistic experiments. Results show that PGC-1α enhances mitochondrial oxidative phosphorylation (OXPHOS) via ASCL1-positive feedback, and that PGC-1α inhibition or overexpression modulates proliferation and tumor formation.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/pgc-1-drives-small-cell-neuroendocrine-cancer-progression-toward-an-ascl1-expressing-subtype-with-increased-mitochondrial-capacity/340568/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/pgc-1-drives-small-cell-neuroendocrine-cancer-progression-toward-an-ascl1-expressing-subtype-with-increased-mitochondrial-capacity/340568.png","ImageObject",300,407,{"name":92,"@type":93},"Clementine","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What role does PGC-1α play in small cell neuroendocrine cancer progression?","Question",{"text":112,"@type":113},"The study identifies PGC-1α as a driver of SCNC progression and subtype determination by regulating mitochondrial oxidative phosphorylation (OXPHOS).","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How is PGC-1α connected to the ASCL1-expressing subtype?",{"text":117,"@type":113},"PGC-1α correlates with increased ASCL1 expression through a positive feedback mechanism, and the ASCL1 subtype shows heightened PGC-1α and OXPHOS activity.",{"name":119,"@type":110,"acceptedAnswer":120},"What effects do manipulating PGC-1α have on SCNC behavior and tumors?",{"text":121,"@type":113},"PGC-1α inhibition diminishes OXPHOS, reduces SCNC proliferation, and blocks SCN prostate tumor formation; PGC-1α overexpression increases OXPHOS, triples tumor formation rate, and promotes commitment to the ASCL1 lineage.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},340568,1790154425,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},1374391974564,"https://ap-avatar.wpscdn.com/avatar/14000253aa45c000a9e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779874745381141002","RESEARCH ARTICLE  \nCELL BIOLOGY  \n OPEN ACCESS  \nPGC-1α drives small cell neuroendocrine cancer progression toward an ASCL1-expressing subtype with increased mitochondrial capacity  \nGrigor Varuzhanyana,1, Chia-Chun Chenb, Jack Freelandb,c, Tian Heb, Wendy Trana, Kai Songd, Liang Wanga, Donghui Chenga,e, Shili Xub,f,g , Gabriella A. Dibernardoe, h, Favour N. Esedebeb, i, Vipul Bhatiaj, k, Mingqi Hanl, Evan R. Abtb , Jung Wook Parkm, Sanaz Memarzadehb,e,g, h, n,o,  \nDavid B. Shackelfordg, l, John K. Leej, k, Thomas G. Graeberb,e,f,g, i, p,q, Orian S. Shirihaib,c, r,s, and Owen N. Wittea, b,e,g,o,t,1 Affiliations are included on p. 11.  \nContributed by Owen N. Witte; received August 29, 2024; accepted October 25, 2024; reviewed by Charles M. Rudin and Bruce M. Spiegelman  \nAdenocarcinomas from multiple tissues can converge to treatment-resistant small cell neuroendocrine (SCN) cancers composed of ASCL1, POU2F3, NEUROD1, and YAP1 subtypes. We investigated how mitochondrial metabolism influences SCN cancer (SCNC) progression. Extensive bioinformatics analyses encompassing thousands of patient tumors and human cancer cell lines uncovered enhanced expression of proliferator-activatedreceptor gamma coactivator 1-alpha (PGC-1α), a potent regulator of mitochondrial oxidative phosphorylation (OXPHOS), across several SCNCs. PGC-1α correlated tightly with increased expression of the lineage marker Achaete-scute homolog 1,(ASCL1) through a positive feedback mechanism. Analyses using a human prostate tissue-based SCN transformation system showed that theASCL1 subtype has heightened PGC-1α expression and OXPHOS activity. PGC-1α inhibition diminished OXPHOS, reduced SCNC cell proliferation, and blocked SCN prostate tumor formation. Conversely, PGC-1α overexpression enhanced OXPHOS, validated by small-animal Positron Emission Tomography mitochondrial imaging, tripled the SCN prostate tumor formation rate, and promoted commitment to theASCL1 lineage. These results establish PGC-1α as a driver of SCNC progression and subtype determination, highlighting metabolic vulnerabilities in SCNCs across different tissues.  \nPGC-1a | ASCL1 | oxidative phosphorylation | lung cancer | prostate cancer  \nEpithelial cancers from various tissues, including the prostate, lung, and bladder, can converge to an aggressive small cell neuroendocrine (SCN) phenotype under targeted treatments (1–3). These phenotypically similar, small cell neuroendocrine cancers (SCNCs) are classified as high-grade, poorly differentiated small cell carcinomas that commonly express neuroendocrine markers like chromograninA (CHGA), neural cell adhesion molecule 1 (NCAM1), and synaptophysin (SYP) (4) . With a dismal median survival rate between 7 to 16 mo (5), there is a pressing need for a better mechanistic understanding of disease progression to inform new therapeutic strategies.  \nSCNCs are composed of multiple subtypes defined by prominent expression of lineage markers. This is best exemplified in SCLC, which is categorized into ASCL1, NEUROD1, POU2F3, and YAP1 subtypes (6, 7) . Recent studies have identified corresponding subtypes in SCN prostate cancer, including ASCL1, POU2F3/ASCL2, and NEUROD1 (8–10). A growing body of research across numerous SCNC models has highlighted the plastic nature of differentiation toward and between these subtypes (6, 7, 11–13) .  \nComplementing the molecular heterogeneity within SCNCs, recent studies have begun to highlight the metabolic diversity across different SCLC subtypes (14–18). A correlation has been observed between ASCL1 expression levels and a dependence on inosine monophosphate dehydrogenase, a key enzyme in guanosine biosynthesis (14). Thus, metabolic reprogramming might regulate lineage plasticity in SCNCs.  \nA key aspect of metabolic reprogramming in cancer is the shift toward aerobic glycolysis (Warburg effect), characterized by increased glucose consumption and lactate secretion, even in the presence of ampleoxygen (19). This seminal ","cbCaipnYdaLnXSdb","https://ap.wps.com/l/cbCaipnYdaLnXSdb","pdf",1992163,12,"English","# Significance\n# Model overview and clinical problem\n## SCN cancer subtypes and lineage markers\n## Metabolic reprogramming and mitochondrial function\n## Study findings on PGC-1α, ASCL1, and OXPHOS","[{\"question\":\"What role does PGC-1α play in small cell neuroendocrine cancer progression?\",\"answer\":\"The study identifies PGC-1α as a driver of SCNC progression and subtype determination by regulating mitochondrial oxidative phosphorylation (OXPHOS).\"},{\"question\":\"How is PGC-1α connected to the ASCL1-expressing subtype?\",\"answer\":\"PGC-1α correlates with increased ASCL1 expression through a positive feedback mechanism, and the ASCL1 subtype shows heightened PGC-1α and OXPHOS activity.\"},{\"question\":\"What effects do manipulating PGC-1α have on SCNC behavior and tumors?\",\"answer\":\"PGC-1α inhibition diminishes OXPHOS, reduces SCNC proliferation, and blocks SCN prostate tumor formation; PGC-1α overexpression increases OXPHOS, triples tumor formation rate, and promotes commitment to the ASCL1 lineage.\"}]","PGC-1α drives small cell neuroendocrine cancer progression toward an ASCL1-expressing subtype with increased mitochondrial capacity | PDF",1790037394,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/97e2ed4930d4ab6344059fbcb2bd6c63.webp",983,1316,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/128a7d24d2559eba6082e0e24e95e3fb.webp",982,1315,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3509fbe3717cafd1dac3d6fd0331a450.webp",981,1313,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d4217b55d0a6e0f253f102a34e0cdaa1.webp",980,1312]